Fiasp

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
R/0028	Renewal of the marketing authorisation.	24/06/2021	18/08/2021	SmPC, Labelling and PL	Renewal of the marketing authorisation
WS/2056	This was an application for a variation following a worksharing procedure according to Article 20 of	10/06/2021	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	Commission Regulation (EC) No 1234/2008. B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product				
PSUSA/1749/202009	Periodic Safety Update EU Single assessment - insulin aspart	06/05/2021	n/a		PRAC Recommendation - maintenance
WS/1997	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	11/03/2021	n/a		
IAIN/0027	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	19/02/2021	n/a		
WS/1901	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/09/2020	18/08/2021	SmPC, Annex II, Labelling and PL	
IB/0023	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a	17/04/2020	n/a		

	biological/immunological medicinal product				
PSUSA/1749/201909	Periodic Safety Update EU Single assessment - insulin aspart	17/04/2020	n/a		PRAC Recommendation - maintenance
IB/0022	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	30/03/2020	n/a		
II/0018/G	This was an application for a group of variations. The SmPC sections 1, 2, 3, 4.2, 4.4, 6.3, 6.4, 6.5 and 6.6 of the SmPC have been updated to include information on the new 1.6 ml PumpCart cartridge. Please refer to Attachment 1 which includes all approved changes to the Product Information. The Labelling and PL have been updated accordingly. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	12/03/2020	30/09/2020	SmPC, Labelling and PL	The SmPC sections 1, 2, 3, 4.2, 4.4, 6.3, 6.4, 6.5 and 6.6 of the SmPC have been updated to include information on the new 1.6 ml PumpCart cartridge. Please refer to Attachment 1 which includes all approved changes to the Product Information. The Labelling and PL have been updated accordingly.
IAIN/0021	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	11/02/2020	n/a		

IA/0019	A.7 - Administrative change - Deletion of manufacturing sites	06/12/2019	n/a		
WS/1687	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	05/12/2019	n/a		
II/0016	Update of the SmPC section 4.8 with data from an updated safety pool, further to assessment of the last PSUR assessment for insulin aspart (EMEA/H/C/PSUSA/00001749/201809). This update is based on 3 efficacy and safety studies: NN1218-3852 (52 week) – a study of Fiasp compared to insulin aspart both in combination with insulin detemir in adults with Type 1 Diabetes; NN1218-3854 a study of Continuous Subcutaneous Insulin Infusion of Fiasp compared to NovoRapid in adults with Type 1 Diabetes; NN1218-4131 a study of Fiasp compared to NovoRapid both in combination with insulin degludec in adults with Type 1 Diabetes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	19/09/2019	30/09/2020	SmPC, Labelling and PL	The SmPC section 4.8 has been updated with new frequencies for allergic reactions, lipodystrophy and injection site/ infusion site reactions in the section "Description of selected adverse reactions". Data on Infusion site reaction adverse events in the population on CSII (i.e. study 3854 and 3931) has been presented separately. Please refer to the SmPC for further details. The Labelling and PL have been updated accordingly.
II/0010	Extension of Indication to include treatment of children and adolescents aged 1 year and above	27/06/2019	31/07/2019	SmPC, Annex II, Labelling	Please refer to Scientific Discussion Fiasp-H-C-4046-II-10

	based on data from the phase 3b clinical trial NN1218-4101, supported by data from the Clinical Pharmacology trials NN1218-4371 and clinical study NN1218-3888 which was included in the initial MAA. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC and the corresponding sections of the Package Leaflet are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make other non-related minor or editorial changes were implemented throughout the EU PI to increase readability/consistency. An updated RMP version 3.1 was agreed during the procedure. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one			and PL	
IG/1092	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	12/07/2019	n/a		
PSUSA/1749/ 201809	Periodic Safety Update EU Single assessment - insulin aspart	26/04/2019	01/07/2019		Based on the post-marketing data submitted within this PSUR, the PRAC concludes that anaphylactic reactions should be added to section 4.8 of the SmPC for Fiasp, in line with the SmPC for NovoRapid and NovoMix. Following 7 new reported cases of medically confirmed systemic allergic reactions for Fiasp and the already established evidence suggesting a causal relationship between insulin

					aspart and anaphylactic reactions, the updates to the section 4.8 of SmPC for Fiasp are justified.
IB/0014	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	29/06/2019	31/07/2019	SmPC, Labelling and PL	
IB/0013	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	15/05/2019	n/a		
IB/0012	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	26/04/2019	n/a		
WS/1564	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	04/04/2019	n/a		
IG/1038	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	14/01/2019	n/a		
IAIN/0007	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging	12/10/2018	n/a		

	site				
WS/1405	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	19/07/2018	n/a		
PSUSA/1749/ 201709	Periodic Safety Update EU Single assessment - insulin aspart	12/04/2018	n/a		PRAC Recommendation - maintenance
II/0003/G	This was an application for a group of variations. Update of the RMP to upgrade the risk of mix-up between basal and bolus insulin from a potential to an important identified risk (RMP version 2.1); in addition, to update the secondary packaging material design and change colour of selected plastic components from yellow to red, consequently section 4.2 of the SmPC is being updated to no longer include the word "yellow" due to the new proposed colour coding of Fiasp. The PL has been updated accordingly. A communication to Health Care Professionals and Patients regarding similarity of Fiasp and Tresiba products that are currently on the market has been agreed. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished	09/03/2018	12/04/2018	SmPC and PL	To mitigate the risk of medication errors due to mix up between Fiasp and Tresiba, the MAH has proposed 2 new risk minimisation measures (RMMs): (1) introduction of new colour coding for Fiasp and (2) use of educational materials as part of a communication strategy prior to the new colours being implemented. The proposed new colour coding for Fiasp comprise changes from yellow with a white contrast to yellow with a red contrast on the labels and cartons and from yellow to red for plastic components for the prefilled pens. As a result of this group of variations, section 4.2 of the SmPC is being updated to no longer include the word "yellow" due to the new proposed colour coding of Fiasp: "FlexTouch is colour coded yellow and accompanied by a package leaflet with detailed instructions for use to be followed". The PL has been updated accordingly. The risk management plan (RMP) has been updated accordingly to provide background information on the

	product formulation - Change that affects the product information C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				medication errors, upgrading of the safety concern of 'Medication errors (mainly wrong drug administered)' from an important potential risk to an important identified risk, details of the colour coding changes and details of the proposed communications. The targeted questionnaire to follow up reports of medication errors has been additionally updated. Changes unrelated to medication errors, mainly concerning extent of use of the product, have also been made to the RMP.
IB/0005	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/03/2018	25/02/2019	SmPC, Annex II, Labelling and PL	
WS/1132	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS	05/05/2017	n/a		
IAIN/0001	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	16/02/2017	n/a		